echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Takeda reported the latest results of mobocertinib, further confirming the clinical benefits of patients with EGFR exon 20 insertion + mNSCLC

    Takeda reported the latest results of mobocertinib, further confirming the clinical benefits of patients with EGFR exon 20 insertion + mNSCLC

    • Last Update: 2021-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    −This result shows that the median overall survival of the oral targeted therapy drug mobocertinib is 24 months, and a variety of EGFR exon 20 (Exon20) insertion variants all have remissions


    TSE:4502/NYSE:TAK NSCLC video

    Suresh S.


    The analysis from the Phase 1/2 trial included patients with EGFR exon 20 insertion + mNSCLC who had previously received platinum-containing chemotherapy.


    International Society for Lung Cancer Research (IASLC) 2020 World Conference on Lung Cancer (WCLC)

    The measured safety is manageable and consistent with previous findings.


    Dr.


    mobocertinib previously passed the FDA Breakthrough Therapy Certification in April 2020, and entered the New Drug Application (NDA) priority review in April 2021.


    Takeda has set up the Expansion Access Point (EAP), and patients may be eligible for mobocertinib during the regulatory approval of the drug under development.


    Here

    Please learn more about the layout of Takeda Oncology at this year's ASCO annual meeting .


    Learn more about Takeda's Oncology Department's layout at this year's ASCO annual meeting.


    About the Phase 1/2 trial

    About the Phase 1/2 trial

    This phase 1/2 trial evaluates the safety, pharmacokinetics, and anti-tumor activity of oral mobocertinib in patients with non-small cell lung cancer (NSCLC).


    The previous population effectiveness analysis of platinum-containing treatment investigated 114 patients with EGFR exon 20 insertion + mNSCLC who received platinum-containing treatment and received mobocertinib 160 mg once daily in this phase 1/2 trial.


    About EGFR exon 20 insertion + mNSCLC

    About EGFR exon 20 insertion + mNSCLC

    Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.


    Diagnosis 1,2 3-7

    Takeda is committed to continuing EGFR exon 20 insertion + mNSCLC the field of research and development, with a view to approximately 30,000 cases worldwide (including the United States alone, 3,000 cases) patients were diagnosed of the disease each year to provide a targeted treatment options 3,4 .


    3,4

    Takeda's commitment to oncology

    Takeda's commitment to oncology

    Our core research and development mission is to deliver new drugs to cancer patients around the world through our commitment to science, breakthrough innovation, and passion for improving the lives of patients.


    Takeda Pharmaceutical Co.


    TSE: 4502/NYSE: TAK https:// hintimportant hint

    For the purposes of this article, "press release" refers to this document, any oral statement, any question-and-answer session, and any written or oral materials discussed or distributed by Takeda Pharmaceutical Co.


    Companies directly or indirectly held by Takeda through investment are independent entities.
    In this press release, sometimes for convenience, "Takeda" is used as a collective term for Takeda and its subsidiaries.
    Similarly, words like "we" (subject and object forms) and "our" are also collective names for subsidiaries or represent employees of the company.
    These expressions are also used in situations that have no practical meaning and do not involve a particular company or certain companies.

    Forward-looking statements

    Forward-looking statements

    This press release and any materials distributed in connection with it may contain forward-looking statements, views or opinions related to Takeda’s future business, future conditions and operating performance, including Takeda’s estimates, forecasts, goals and plans.
    Forward-looking statements often include but are not limited to the following words, such as "target", "plan", "believe", "hope", "continue", "anticipate", "intend", "intend", "ensure", " "Will", "may", "should", "will", "maybe", "expect", "estimate", "forecast" or similar expressions or their negative form.
    These forward-looking statements are based on assumptions about many important factors, including the following factors, which may cause actual results to differ materially from those expressed or implied by the forward-looking statements: The economic situation faced by Takeda’s global operations, including Japan and the United States The macroeconomic environment; competitive pressures and developments; changes in applicable laws and regulations; including global medical reforms; inherent challenges in the development of new products, including the uncertainty of clinical success and the timing of decisions or decision-making by regulatory authorities; new products And uncertainty about the commercial success of existing products; manufacturing difficulties or delays; fluctuations in interest rates and exchange rates; claims or questions about the safety or efficacy of sold products or candidate products; health crises such as the new coronavirus pandemic affect Takeda and The impact of its customers and suppliers, including foreign governments in the country in which Takeda operates or other aspects of its business; the timing and impact of post-merger integration efforts of acquired companies; whether it is possible to divest non-core assets of Takeda’s operations and any such Timing of the divestiture; and other factors described in the latest Form 20-F annual report and other reports submitted by Takeda to the US Securities and Exchange Commission.
    For details, please refer to the Takeda website https:// Or.
    Takeda does not undertake to update any forward-looking statements in this press release or any other forward-looking statements that the company may issue, unless required by law or securities trading rules.
    Historical performance does not represent future performance, and the performance or statement of Takeda in this press release cannot be referred to, nor is it an estimate, forecast, guarantee or conjecture of Takeda’s future performance.

    https://informationMedical information

    The products mentioned in this press release may not be on the market in all countries, or may be sold under different trademarks, or used for different diseases, or in different dosages, or have different effects.
    Any information contained in this article should not be regarded as an application, promotion or advertisement of any prescription drugs, including those drugs under development.



    Leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.